MediWhale Makes a Big Splash with $12 Million in Funding to Expand Health Diagnostics Technology

MediWhale, an innovative leader in AI-powered health diagnostics, has successfully raised $12 million in its latest funding round, marking a significant milestone in its mission to revolutionize preventative healthcare. Founded in 2016 in South Korea, MediWhale specializes in non-invasive retina scans that aim to detect risks of heart and kidney diseases long before symptoms manifest. The company’s groundbreaking Reti-Intelligence suite of services leverages cutting-edge deep learning algorithms to transform routine eye exams into powerful diagnostic tools, thereby empowering healthcare providers to intervene early and enhance patient outcomes. The newly acquired funding will be instrumental in accelerating MediWhale's research and development efforts, ultimately paving the way for the expansion of its innovative services across new markets. With product approvals already secured in eight regions across Europe and Asia, including the EU, UK, Australia, and Korea, MediWhale is also in the process of achieving FDA approval, which will catalyze its growth in the U.S. market. This funding round reflects the growing confidence in MediWhale’s mission to make preventative care more affordable, accessible, safe, and convenient for everyone. By harnessing the potential of AI technology, MediWhale is poised to lead a new era of proactive health management, fundamentally changing how we approach disease prevention and ensuring that millions can benefit from early diagnosis.